Know Cancer

or
forgot password


Phase 2
18 Years
N/A
Not Enrolling
Male
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms

Thank you

Trial Information

Inclusion Criteria

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

598-CL-008

NCT ID:

NCT00048659

Start Date:

Completion Date:

June 2004

Related Keywords:

  • Hormone-Refractory Prostate Cancer
  • Prostatic Neoplasms
  • Androgen-independent prostate cancer
  • Neoplasms
  • Prostatic Neoplasms

Name

Location

Washington University School of MedicineSaint Louis, Missouri  63110
Henry Ford HospitalDetroit, Michigan  48202
Virginia Mason Medical CenterSeattle, Washington  98111
Memphis Cancer CenterMemphis, Tennessee  38119
Alaska Clinical Research Center, LLCAnchorage, Alaska  99508
Western Clinical Research, Inc.Torrance,, California  90505-4763
San Bernardino Urological AssociatesSan Bernardino, California  
Shands HospitalGainesville, Florida  
Sylvester Comprehensive Cancer CenterMiami, Florida  
Georgia Urology,PA Research InstituteAtlanta, Georgia  
University of Illinois, Department of UrologyChicago, Illinois  
University of Chicago, Section of Hematology/OncologyChicago, Illinois  
Michiana Hematology/OncologySouth Bend, Indiana  
The Urologic Institute of New OrleansGretna, Louisiana